Dragonfly to receive payment for the first Opt-In from AbbVie as part of a multi-target collaboration launched just over 1 year ago. "AbbVie is committed to delivering improved treatment options to ...

Dragonfly will use its TriNKET™ platform to develop drug candidates directed to multiple targets for autoimmune disorders, and oncology. AbbVie receives exclusive options to license a number of ...

Dragonfly and AbbVie expand their existing collaboration in oncology and autoimmune disease to develop additional drug candidates in immune-mediated diseases using Dragonfly's proprietary Tri-specific ...

In the ASCO Developmental Therapeutics – Immunotherapy Session, Dr. Howard Safran presents encouraging data on Dragonfly's phase 1/2 study of DF1001, an immune engaging TriNKET ® targeting HER2 in ...

metastatic breast cancer (mBC) and non-small cell lung cancer (NSCLC). WALTHAM, Mass., Feb. 15, 2024 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing ...

In Phase 1 DF1001 was well-tolerated and showed encouraging pharmacodynamic effects and clinical response, with tumor burden reductions across several tumor types including in HER2-low, heavily ...

BOSTON, Nov. 7, 2024 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical-stage biotechnology company developing novel immunotherapies, today announced the company will deliver poster ...

Dragonfly to receive payment for the first Opt-In from AbbVie as part of a multi-target collaboration launched just over 1 year ago. WALTHAM, Mass., Jan. 12, 2021 /PRNewswire/ -- Dragonfly ...

DF9001 is currently being evaluated for the treatment of Non-Small Cell Lung Cancer, Renal Cell Carcinoma and Head and Neck Squamous Cell Carcinoma DF6215 is currently being evaluated for the ...

Bulletin: ...WINTER WEATHER ADVISORY REMAINS IN EFFECT FROM 3 PM THIS AFTERNOON TO 6 AM EST SUNDAY... * WHAT...Mixed precipitation expected. Total snow and sleet ...